Author

S. Mäki

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

A. Haveri· 1 shared A. Kipar· 1 shared A. Pasternack· 1 shared A. R. Mäkelä· 1 shared H. Ugurlu· 1 shared I. Rissanen· 1 shared J. Hepojoki· 1 shared J. T. Huiskonen· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Haveri

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Intranasal inhibitor broadly blocks SARS-CoV-2 including recent highly immunoevasive Omicron subvariants

A. R. Mäkelä, H. Ugurlu, L. Hannula, P. Salminen, R. Kant, R. Fagerlund, S. Mäki, A. Haveri, T. Strandin, L. Kareinen, J. Hepojoki, L. Levanov, A. Pasternack, R. A. Naves, O. Ritvos, , K. Saksela

This paper describes a novel intranasal inhibitor, TriSb92, that effectively neutralizes SARS-CoV-2 and recent Omicron subvariants, offering protection against infection in mice.

bioRxiv · Dec 28, 2021 · PreprintMicrobiology